FLUCELVAX QUADRIVALENT Drug Insight
“FLUCELVAX QUADRIVALENT Drug Insight and Market Forecast – 2032” report provides comprehensive insights about FLUCELVAX QUADRIVALENT for seasonal influenza in the six major markets. A detailed picture of the FLUCELVAX QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this report along with a detailed description of the FLUCELVAX QUADRIVALENT for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FLUCELVAX QUADRIVALENT market forecast analysis for seasonal influenza in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.
FLUCELVAX QUADRIVALENT (influenza vaccine) is a subunit influenza vaccine manufactured using cell-derived candidate vaccine viruses (CVV) that are propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line. These cells were adapted to grow freely in suspension in a culture medium. The virus is inactivated with β-propiolactone, disrupted by the detergent cetyltrimethylammonium bromide, and purified through several process steps. Each of the four virus strains is produced, purified separately, and then pooled to formulate the quadrivalent vaccine.
In 2019, the company announced that European Commission has issued marketing approval for its new cell-based seasonal influenza vaccine, FLUCELVAX TETRA influenza, the first cell-based quadrivalent influenza vaccine (QIVc) available in Europe and is licensed for use in people 9 years and above.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the FLUCELVAX QUADRIVALENT description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
- Elaborated details on FLUCELVAX QUADRIVALENT regulatory milestones and other development activities have been provided in this report.
- The report also highlights the FLUCELVAX QUADRIVALENT research and development activities in seasonal influenza across the United States and Europe.
- The report also covers the patents information with expiry timeline around FLUCELVAX QUADRIVALENT.
- The report contains forecasted sales of FLUCELVAX QUADRIVALENT for seasonal influenza till 2032.
- Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
- The report also features the SWOT analysis with analyst views for FLUCELVAX QUADRIVALENT in seasonal influenza.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
FLUCELVAX QUADRIVALENT Analytical Perspective by DelveInsight
- In-depth FLUCELVAX QUADRIVALENT Market Assessment
This report provides a detailed market assessment of FLUCELVAX QUADRIVALENT for seasonal influenza in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.
- FLUCELVAX QUADRIVALENT Clinical Assessment
The report provides the clinical trials information of FLUCELVAX QUADRIVALENT for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.
- In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FLUCELVAX QUADRIVALENT dominance.
- Other emerging products for seasonal influenza are expected to give tough market competition to FLUCELVAX QUADRIVALENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FLUCELVAX QUADRIVALENT in seasonal influenza.
- Our in-depth analysis of the forecasted sales data of FLUCELVAX QUADRIVALENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FLUCELVAX QUADRIVALENT in seasonal influenza.
- What is the product type, route of administration and mechanism of action of FLUCELVAX QUADRIVALENT?
- What is the clinical trial status of the study related to FLUCELVAX QUADRIVALENT in seasonal influenza and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FLUCELVAX QUADRIVALENT development?
- What are the key designations that have been granted to FLUCELVAX QUADRIVALENT for seasonal influenza?
- What is the forecasted market scenario of FLUCELVAX QUADRIVALENT for seasonal influenza?
- What are the forecasted sales of FLUCELVAX QUADRIVALENT in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom?
- What are the other emerging products available and how are these giving competition to FLUCELVAX QUADRIVALENT for seasonal influenza?
- Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?